Sobi: sänkt fair value till 190 kronor

AKTIE: Svag effekt av medicinen Doptelet i test på cancerpatienter försämrar Sobis framtidsutsikter och Morningstars analytiker sänker fundamentalt beräknat fair value för aktien från 207 till 190 kronor (2020-10-09).

Morningstar Equity Analysts 2020-10-09 | 9:14
Facebook Twitter LinkedIn

analys Sobi aktie, sänkt fair value

Analyst Note | Oct 09, 2020

We have lowered our Swedish Orphan Biovitrum fair value estimate to SEK 190 from SEK 207 following the disappointing results for avatrombopag (Doptelet) in chemotherapy-induced thrombocytopenia. Patients taking the medication did not see significantly fewer platelet transfusions, or fewer reductions or delays in chemotherapy, due to thrombocytopenia (the composite primary endpoint) relative to patients in the placebo arm. Although SOBI attributes this failure to an unexpectedly strong performance for placebo patients, this is still a setback for the drug in one of its largest market opportunities, and we have lowered our peak sales assumptions for the drug to $300 million from $700 million. Most of our sales forecast now stems from approval in ITP (approved in the U.S., filed in Europe). We continue to view SOBI's franchise as lacking an economic moat, despite current strong sales for the firm's hemophilia therapies Elocta and Alprolix, and this setback reduces SOBI's ability to diversify its product revenue away from hemophilia therapies, which are vulnerable to competition from Roche's Hemlibra (approved) as well as RNA-based and gene therapies in development. SOBI also saw disappointing data for gout therapy SEL-212 relative to standard of care Krystexxa in a phase 2 trial in September, leading us to question the decision to push forward into phase 3 studies and whether the drug has the ability to displace this approved competitor. However, we had not modeled significant revenue potential for the gout drug, and this did not have a significant impact on our valuation.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

För att läsa denna artikel krävs medlemskap

Bli medlem gratis

Tillgång till över 1000 aktieanalyser globalt, via Morningstar Direct

Läs mer

Facebook Twitter LinkedIn

About Author

Morningstar Equity Analysts  Morningstar stock and fund analysts cover 2,000 mutual funds, 2,100 equities, and 300 exchange-traded funds.

© Copyright 2021 Morningstar, Inc. Alla rättigheter förbehållna.

Användarvillkor        Privacy Policy